• ADDITIONAL EVENT SPEAKERS

    A to K

  • ED ADDISON, BSEE, MS, MBA

    CEO of Cloud Pharmaceuticals, a Research Triangle Park Company from Duke University

    Ed Addison is Chairman and CEO of Cloud Pharmaceuticals, a Research Triangle Park company from Duke University that applies AI to drug design and discovery, achieving unprecedented results. Cloud Pharmaceuticals has designed new drug candidates for cancer, metabolic diseases, and other indications. With over 30 years experience, Ed is on the advisory board and/or board of directors of a number of companies deploying exponential technologies in life sciences and artificial intelligence, including Drug Logic, Parallel Profile, New Life Cures, and Quantum Cures Foundation.

    With a technical background in artificial intelligence and Bio-IT, and a strong business development and capital raising background, Ed is an established serial entrepreneur of disruptive ventures. Ed started 6 companies, funded 4 of them and exited 3. He has twice been named "Entrepreneur of the Year." He has advised 7 venture capital funds and over 20 early stage ventures. His expertise is in launching new technology ventures and new technology products.

    Ed is an adjunct professor of engineering management, entrepreneurship and MBA courses. He has previously taught artificial intelligence, computer science, systems engineering and/or bioinformatics for several universities, including NC State University, Stevens Institute of Technology and Johns Hopkins University. Ed holds a BSEE from Virginia Tech, two MS degrees in electrical and biomedical engineering from Johns Hopkins, and an MBA from Duke University with a focus in healthcare. He did a sabbatical year at MIT in artificial intelligence in 1985.

     

  • CATHY CATHER

    CEO of ParallelProfile

    Cathy Cather is the CEO of ParallelProfile. Cathy has 25 years of experience in benefits consulting and enterprise deals, and with leading the Health Care Strategy Practice at Willis Towers Watson. She has been instrumental in growth acceleration at HealthEnquity, Quantum Health, Accolade, United HealthAllies, and Surgery Plus.

     

  • DR. OLIVER CHIKUMBO, PhD

    Chief Data Scientist at Living PlanIT AG.

    Dr. Oliver Chikumbo, Ph.D. is a Chief Data Scientist at Living PlanIT AG in areas spanning system identification, optimal control theory, evolutionary multi-objective optimization, exploratory data analyses, virtual reality visualization for hyperspaces, multi-criterion decision-making, and high-performance computing.

     

    Application areas have currently been focused on “wicked problems” that define a science area, which amalgamates the traditional disciplinary and interdisciplinary scientific activities with social complexity. He has 23 years of research experience and academic qualifications in resource & environmental management and systems engineering from the Australian National University.

     

  • DR. NICOLAS CHRONOS, MD, FACC, FESC

    Consulting Professor of Medicine and Cardiology at Stanford University

    Dr. Nicolas Chronos is an interventional cardiologist well known for his pioneering research in the treatment of heart disease. He is an expert in cardiac regenerative medicine, cardiovascular medical device assessment, and translational cardiovascular medicine. His passion in the industry has resulted in years of extensive experience with the preclinical and clinical development of cardiovascular medicines, medical devices, and biologics. Many of the devices and products developed in his career have been approved by the FDA and are now in clinical utility. Dr. Chronos is a Fellow of the American College of Cardiology, the European Society of Cardiology, and the Royal College of Physicians of London. He has held previous academic appointments at Duke and Stanford Universities. He is currently on the faculty of Stanford University as a consulting professor of medicine and cardiology.

     

    Dr. Chronos’s distinguished career began with a degree in medicine and surgery from the Royal Free Hospital School of Medicine at the University of London in 1987. After this, he trained in cardiology and interventional cardiology at the Royal Brompton National Heart and Lung Institute in London. In 1992, Dr. Chronos was awarded a British Heart Foundation International Fellowship and continued his research in interventional cardiology in the United States at Emory University School of Medicine. He was named Director of Research at the Andreas Gruentzig Cardiovascular Center at Emory University Hospital in 1997. Following this, Dr. Chronos joined Atlanta Cardiology Group in 1999, where he developed and served as CEO of the Saint Joseph’s Translational Research Institute until 2012. From 2004 to 2012, Dr. Chronos was an adjunct partner in Essex Woodlands Health Ventures, the world’s largest health care venture fund, and was a leader on the MedTech team. In 2012, Dr. Chronos established a private cardiology practice (Cardiology Care Clinic) near Atlanta in Lake Oconee, Georgia, where he and his family reside.

  • DAVID CONTORNO

    E Powered Benefits

    David Contorno began his career as a teenager while living in New York and, over the span of more than 20 years, has become a leading expert in employee benefits for large employers across the nation. With sights firmly set on enacting positive change, David created E Powered Benefits, a benefit consulting firm with a clearly defined mission to deliver a different benefit experience based on full transparency. His business model has produced average one-year savings of over 40 percent, along with substantially reduced out-of-pocket costs for employees.

     

    Giving back to the community is something that David has remained committed too. He actively participates in the membership drive for the United Way, assists the local chapter of Habitat for Humanity, and supports the Dove House Child Advocacy Center. He is also on the board of directors for the Charlotte Association of Health Underwriters and a former board member of Healthreach Community Clinic. David also mentors fellow consultants from around the country, sharing his own business model to contribute to the professional growth of others. David is a proud father to two children, Hannah and Ethan. When he is not working, he enjoys traveling, boating, and a variety of outdoor activities.

  • DR. STEVEN A. DAVIS, MD

    Co-founder, Chief Medical Officer and Director of StemBioSys, Inc.

    Dr. Steven A. Davis, MD is the co-founder, chief medical officer and director of StemBioSys, Inc., a privately held cell and culture platform technology company based in San Antonio, Texas. He is on the Board of the Regenerative Medicine Foundation, a trustee of the San Antonio Medical Foundation and adjunct professor at UT Health San Antonio. A practicing dermatologist, Dr. Davis has been principal investigator for 180 clinical trials at the Dermatology Clinical Research Center of San Antonio. He has published widely in both the professional and lay press and aired a syndicated daily radio feature, “Speaking of Health,” on the CBS Radio Network for 34 years. Dr. Davis has a B.A. in economics from Yale University, an M.D. from the University of Texas Southwestern Medical School and completed his residency at the University of California San Francisco Medical School.

  • DR. CHARLES W. DIGGISS

    MBBS, MMM, FRCS is President and Chief Medical Officer of
    Doctors Hospital and the President/CEO of the MedNet Group

    Dr. Charles W. Diggiss, MBBS, MMM, FRCS is President and Chief Medical Officer of Doctors Hospital and the President/CEO of the MedNet Group of companies.
    Dr. Diggiss is a general surgeon whose current practice features advanced laparoscopic applications. He is also the physician leader responsible for Doctor Hospital’s journey to accreditation in high quality and safe patient care with the Join Commission International (JCI). This ‘first in the Caribbean’ distinction was obtained in June 2010. A successful re-accreditation occurred in 2013, and 2016, Dr. Diggiss introduced Laparoscopy in General Surgery at Doctors in 1994, as a launch into innovative technologies in healthcare.

     

    In 2009, he was recognized by the Chamber of Commerce as a finalist nominee for the ‘Business Person of the Year Award,' mainly due to the success of the MedNet Group.

    As CEO of the MedNet Group, Dr. Diggiss oversees the operations of the healthcare practice and management entities, as well as the management of its commercial properties and personnel. As president (and board member) of Doctors Hospital, Dr. Diggiss has launched a new GLOW vision agenda (Grow. Learn. Outreach. Wow!) that positions Doctors Hospital Health System (DHHS) as the leader in innovative practices and technology in the Bahamas.

  • HELEN DISNEY

    CEO, Unblocked

    Helen Disney is Founder and CEO of Unblocked, a hub for Blockchain events,
    education and information and a Founding Partner of Dots Ventures. She was recently
    listed in the inaugural FT Founders 50 list of influential FinTech Founders and has been
    referred to by Barclays as a “Blockchain guru”. She is also a member of techUK’s DLT
    working group and co-founder of the British Blockchain and Frontier Technologies
    Association (BBFTA). Previously, she set up a global platform for news, networking and
    conferences about Blockchain and Distributed Ledgers and worked on educational
    outreach at the Bitcoin Foundation. Prior to moving into fintech, she set up and ran a
    European network of 120 public policy think tanks for 15 years, where her passion was
    healthcare reform and modernization, and she has been regularly featured in the media
    including being a former editorial writer for The Times newspaper.

  • TIFFANY FACILE, BS, MA

    Director for the Regenerative Medicine and Orthopedic/Sports Medicine Research Program

    Sanford Health

    Tiffany Facile, BS, MA is Director of the Regenerative Medicine and Orthopedic/Sport Medicine Research Program at Sanford Health. She received her Bachelor of Science in nursing degree from South Dakota State University in Brookings, South Dakota and her Masters in healthcare administration from Bellevue University in Bellevue, Nebraska.

     

    She has worked as a nurse and administrator for 15 years throughout a variety of settings, including intensive care, clinical research, oncology, pediatric, labor and delivery, perioperative services, medical and surgical inpatient care, acute care, emergency, and numerous outpatient services. Tiffany holds an adjunct instructor position at Augustana University in Sioux Falls, South Dakota. In her current role, Tiffany is responsible for obtaining FDA approval for four clinical trials, managing a regenerative medicine concierge clinic in Munich, Germany, and developing an integrated clinical regenerative medicine program, beginning in orthopedics. She currently sits on the Alliance for Cell Therapy-NOW, a national coalition group.

     

  • ARTHUR E. FRISCH

    Chief Technology Officer & Co-Founder

    Arthur E. Frisch is a chief technology officer, co-founder, Silicon Valley technologist and Bahamian resident. He has had multiple successful starts/exits in the financial technology software sector. Arthur founded i3 Analytics, an insurance technology firm located in Silicon Valley and backed by the Insurance Distribution Investing Group (private equity). Prior to the UAS and insurance industries, Arthur founded Dynamic QR, a marketing technology company that advised Fortune 500s on emerging smartphone technologies such as QR barcodes and geolocation data.

     

    Arthur is a University of Central Florida Legal Studies graduate and has a certificate from Rollins Crummer Graduate School of Business. He is an associate in Insurance Data Analytics (AIDA) designation and a mentor for Supercharger, Asia’s leading financial technology accelerator.

  • STEVE GERST

    MD, MBA, MPH, GMP, CHE

    Steve Gerst, MD, MBA, MPH, GMP, CHE is a graduate of the Columbia University College of Physicians and Surgeons (M.D.) and an Aresty Scholar and Alumnus of the Wharton School of Business at the University of Pennsylvania. He is a graduate of Columbia College (B.A.), Columbia School of Public Health – Health Administration (M.P.H.). Dr. Gerst holds certificates of completion in additional course work from Harvard Business School, Harvard Law School, Harvard School of Public Health. Dr. Gerst is Board Certified in Medical Management and is Diplomat in the American College of Healthcare Executives. 
     

    Dr. Gerst is formerly Senior Consultant and Regional Medical Director for what is now PricewaterhouseCoopers, LLP. He was President of Columbia/HCA’s PPO division nationally under Florida’s former Governor and now Senator, Rick Scott, and Vice President of the corporation (NYSE:HCA). He helped create VISTA Health Plan (now Coventry/Aetna), the largest HMO is south Florida. Prior to that, he was Assistant Vice President of Crawford & Company (Atlanta; NYSE:CRDA/B) the world’s largest independent claims management company, with more than 700 offices in 70 countries.
     

    At Crawford & Company, he built the first nationwide PPO for AIG, Boeing and other Crawford clients with 1,200 hospitals and 120,000 physicians. He began his career consulting to Premier (Charlotte; NASDAQ:PINC), the largest hospital Group Purchasing Organization (GPO) in the U.S. serving 4,000 member hospitals and 150,000 physician’s offices. Throughout his career, he has been involved with over $2 billion in Mergers & Acquisitions Transactions and company turnarounds.

     

    Dr. Gerst is also a founder of ZyVersa Therapeutics which is commercializing pharmaceutical products developed in the laboratories of the University Miami Health Sciences Center, and is a Founder & Principal in Asclepius Life Sciences Fund, LP, an offshore Hedge Fund focused on developing pharmaceutical and biotech companies. He holds his Series 7, 66 and 65 FINRA licenses (SEC) with Craft Capital Management in New York. He is currently working with Pegasus Capital Advisors in New York on several Life Sciences related projects.

    Dr. Gerst also teaches Clinical Informatics at the University of Miami School of Health Sciences and serves an “Entrepreneur–in-Residence” at the University of Miami Miller School of Medicine where he works for the Vice Provost in the Office of the Chief Innovation Officer. He is a frequent lecturer at the University of Miami School of Business at the Undergraduate, Graduate and Executive Healthcare MBA levels. He is currently assisting in the design of a course for the Medical School.
     

    He was previously Dean of the Masters of Science Program for Applied Healthcare Informatics at Bryan University with 5 campuses (Los Angeles, Sacramento, Toronto and Phoenix). Program faculty included the World-Wide Medical Director of Intel Corporation, Chairman of the Board of the American Medical Association, Senior Healthcare Partners from PricewaterhouseCoopers, LLP and Deloitte, LLP, Senior executives and Medical Directors from IBM, Cerner, Epic, United Health Care, McKesson, Universal Health Service (231 hospitals and facilities), Walgreens, DaVita, Oracle Healthcare, and AMIA.

  • STEVEN J. GRECO, PhD

    Director of Research, Rejenevie Therapeutics
    Chief Science Officer, Black Beret Life Sciences and Okyanos Global Health

    Dr. Steven Greco, Ph.D. serves as Director of Research for Advanced Regen Medical
    Technologies and is the Chief Science Officer for Black Beret Life Sciences (BBLS).
    Formally trained as a stem cell biologist, over the past 14 years Dr. Greco has
    contributed original research publications within the fields of regenerative and
    translational medicine. His expanding expertise has covered various regenerative
    research areas, including adipose (fat) tissue-derived stem cells, and he participated
    and managed oncology research at Rutgers University-particularly in the areas of stem
    cells and aging, breast cancer and brain tumors. His studies have primarily focused on
    human adult bone marrow stem cells, namely hematopoietic and mesenchymal stem
    cells. Dr. Greco’s current research focuses on aging biology, specifically approaches to
    restore function to the aging immune system.
    Dr. Greco previously served as Vice President of Research and Development for
    Neurotez Inc., a company focused on Alzheimer's disease drug discovery, early-stage
    development and basic research. During this tenure, Dr. Greco oversaw numerous
    aspects of drug development, from preclinical studies to cGMP manufacturing of a
    biologic to organization of IND-enabling studies and clinical trial design for FDA
    submission. He received both his Ph.D. in stem cell biology and M.S. in biomedical sciences from Rutgers University and his B.A. from Cornell University, where he studied animal
    physiology. Dr. Greco is a contributing author on over 55 research publications and 9
    US and international patents.

  • PROFESSOR JOSHUA M. HARE, MD, FACC

    Senior Associate Dean for Experimental and Cellular Therapeutics and
    Director of the Interdisciplinary Stem Cell Institute (ISCI)

    Professor Joshua M. Hare, MD, FACC is an internationally acknowledged pioneer in the field of stem cell therapeutics, currently seeing and evaluating patients from all over the world for this new experimental therapy. He is the senior associate dean for experimental cellular therapeutics director of the interdisciplinary item cell institute (ISCI), and Louis Lemberg Professor of Medicine at the University of Miami Miller School of Medicine. Professor Hare is also co-founder and chief science officer for Longeveron LLC, a regenerative medicine company based in Miami, Florida.
     

    Longeveron is developing biological solutions for aging and aging-associated diseases through the use of its proprietary mesenchymal stem cells, which are currently being evaluated under FDA-approved clinical trials in the U.S. and the Bahamas. Longeveron is currently conducting four clinical trials in the U.S. and an open-label clinical study registry in the Bahamas. Dr. Hare is an expert in cardiovascular medicine and specializes in heart failure, myocardial infarction, inflammatory diseases of the heart, and heart transplantation.

     

    Dr. Hare led the first randomized allogeneic mesenchymal stem cell (MSC) clinical trial for patients with myocardial infarction and is the principal investigator of multiple other trials for heart failure and cardiovascular disease. Dr. Hare has published more than 260 original research articles, editorials, and review articles, and is the recipient of seven grants from the National Institutes of Health. He holds 10 FDA Investigational New Drug applications for cell-based therapy, including the first in the United States for Idiopathic Pulmonary Fibrosis and Aging Frailty. He is the recipient of three active NIH RO1’s and is the PI of the UM National Heart Lung and Blood Institute Cardiac Cell Therapy Trial Network (CCTRN) center; together these awards fund ~$3M in basic and translational research annually. Educated at the University of Pennsylvania (1984), Johns Hopkins University School of Medicine (1988), The Brigham and Women's Hospital (1994), and Harvard Medical School, Dr. Hare spent 12 years on the faculty at Johns Hopkins University School of Medicine, where he rose to the rank of professor of medicine and biomedical engineering. He became the director of the cardiac transplant and heart failure program in 2004 before joining the faculty at the University of Miami Miller School of Medicine in 2007. Dr. Hare is an elected member of the American Association of Physicians (2011).

     

  • DR. ROBERT HARIRI, MD, Ph.D

    Chairman, Founder and Chief Executive Officer, Celularity

    Dr. Robert Hariri MD, Ph.D. is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. As the chairman, founder and chief executive officer of one of the world’s largest human cellular therapeutics companies, Celularity, and as the founder and former CEO of Celgene Cellular Therapeutics, a division of Celgene Corporation, Dr. Hariri has pioneered the use of stem cells to treat a range of life-threatening diseases and has made transformative contributions to the field of tissue engineering and functional regeneration.

    Dr. Hariri has over 150 issued and pending patents, has authored over 150 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of tumor necrosis factor (TNF). Dr. Hariri was a recipient of the Thomas Alva Edison Award in 2007 and the Fred J. Epstein Lifetime Achievement Award in 2011. He has received numerous other honors for his many contributions to the fields of biomedicine and aviation.


    Dr. Hariri is an adjunct associate professor of pathology at the Icahn School of Medicine at Mount Sinai and a former member of the board of visitors at the Columbia University School of Engineering and Applied Sciences and the Science and Technology Council of the College of Physicians and Surgeons. He is also a member of the scientific advisory board for the Archon X PRIZE, or Genomics, which is awarded by the X PRIZE Foundation.


    Dr. Hariri is also a trustee and vice–chair of the Liberty Science Center and has been appointed Commissioner of Cancer Research by New Jersey Governor Chris Christie.

    Dr. Hariri is the co-founder of Human Longevity, Inc., and is also a member of the board of trustees of the J. Craig Venter Institute. Dr. Hariri completed his undergraduate training at Columbia University School of Engineering and Applied Sciences and Columbia College, and received his M.D. and Ph.D. degrees from Cornell University, where he was the recipient of both the Julian R. Rachele Award and Doctoral Dissertation Award. He received his surgical training at The New York Hospital–Cornell Medical Center. In addition, Dr. Hariri is a jet-rated commercial pilot with thousands of hours of flight time in over 60 different military and civilian aircraft. He has also produced several feature films and documentaries on global societal issues.

  • DR. ROBERT J. HEDYA, M.D., A.B.P.N., D.F.A.P.A.

    Clinical Professor at Georgetown University School of Medicine

    Dr. Robert J. Hedya, M.D., A.B.P.N., D.F.A.P.A. is a pioneer in precision medicine and functional medicine, and is a clinical professor at Georgetown University School of Medicine. His approach offers proven, data-driven and comprehensive holistic approaches to health. In addition to his private practice, Dr. Hedaya is a visionary in the field of psychiatry and teaches fellow physicians, medical students, and other healthcare clinicians. Referred to as a “doctor’s doctor,” Dr. Hedaya has treated many fellow physicians in his practice.
     

    Dr. Hedaya teaches physicians regularly at the Institute for Functional Medicine, the Walsh Research Institute and Georgetown University School of Medicine, and is the author of three books and hundreds of articles. Dr. Hedaya’s medical approach focuses on the detailed evaluation and bi-directional interactions between and among a person’s hormonal system, immune system, gastrointestinal system, nutrition, environment, inflammation, infection, genetics, detoxification, cell signaling, life circumstance, age, and gender. He is board-certified by the American Board of Psychiatry and Neurology, and is a distinguished fellow of the American Psychiatric Association.
     

    He is certified as proficient in psychopharmacology by The American Society of Clinical Psychopharmacology. Dr. Hedaya has been recognized as a master clinician in functional medicine by the Institute for Functional Medicine. Dr. Hedaya trained and specialized in psychiatry at Georgetown University Medical Center and at the National Institute of Mental Health. He continued on to acquire advanced training in functional medicine and orthomolecular psychiatry. Since 1983, Dr. Hedaya has managed an active, private clinical practice. He has been a consultant to the National Institute of Mental Health and was selected to teach the first psychoendocrinology course at the Georgetown University Medical Center Department of Psychiatry. Dr. Hedaya presents and teaches at medical and professional conferences nationwide.

  • DR. STEVEN JAMES KELLNER, Ph.D

    Co-founder, Chief Scientific Officer
    Senior VP of International Research & Development of Med Cell Bahamas Ltd.

    Dr. Steven James Kellner, PhD is the Co-founder, Chief Scientific Officer and Senior VP of International Research & Development at Med Cell Bahamas Ltd. He is a British researcher and stem cell specialist, and currently leads Med Cell’s International Research & Development programs. He earned his doctorate from the University of Zurich, Switzerland, and has over 30 years of leadership experience in the medical field in the following roles: Executive Director and Head of Medical and Drug Regulatory Affairs of Ciba Vision, Vice President and Head of Medical Affairs of Novartis Ophthalmics, Head of Ophthalmology at the Veterinary Faculty of University Berne, and Medical Advisor at Virbac AG, Switzerland.

     

    Dr. Kellner has executed a variety of R&D projects and pre-clinical studies, and is the author of numerous scientific publications. He mentors young biotech start-up companies and actively seeks and finds collaboration with other research institutes and local governments. He is a fellow of the Royal Microscopical Society FRMS and member of the board of certified eye specialist CertVOphthal. Dr. Kellner is editor-in-chief of the Journal of Stem Cell Research & Therapeutics and the Journal of Advanced Research on Alzheimer’s & Parkinson’s Disease (ARAP). He is also the editor of Archives in Neurology and Neuroscience. 

     

    With Med Cell, he is responsible for worldwide research projects and clinical trials for diseases such as Alzheimer’s disease, Parkinson’s disease, Diabetes T1 and T2, osteoarthritis and retinal disease.

    Dr. Kellner’s research has led to several innovations, such as a patented methodology for the present and future use of the secretome of adipose-derived mesenchymal stem cells.